Riskpilot← Back to searchSign inGet full accessFrontier Pharma AB
ABActiveOrg 5566453097Economic activity was not specified by tax authority · NACE 0000Est. 20030 employees
Revenue 2024
SEK 0
EBITDA margin
—
0% vs 2023
Equity ratio
10.5%
Financial strength
Net profit 2024
SEK 1,1M
-85% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -17K | +0% |
| Net profit | SEK 1,1M | -85% |
| Total assets | SEK 13,6M | -46% |
| Equity | SEK 1,4M | -82% |
| Employees | 0 | — |
Legal name
Frontier Pharma AB
Org number
5566453097
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
23 juni 2003
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Niklasson, Bo Johan Niklas Niklasson, Lena Marie
Company purpose
Bolaget skall bedriva tillverkning och försäljning av kemisk- tekniska medicinska produkter, köp och försäljning av fastigheter och värdepapper samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | — | −14 | −12 | −11 | −13 | −10 | −26 | −16 | −17 | −17 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −14 | −12 | −11 | −13 | −10 | −26 | −16 | −17 | −17 |
| Net financials | 4 029 | 3 764 | 4 076 | 4 830 | 5 230 | 5 541 | 7 017 | 6 507 | 6 414 | 525 |
| Profit before tax | 4 500 | 4 343 | 4 704 | 5 419 | 5 867 | 6 121 | 7 017 | 7 315 | 7 529 | 1 178 |
| Tax | −0 | −2 | −1 | −4 | −4 | −13 | −13 | −14 | −27 | −51 |
| Net profit | 4 500 | 4 341 | 4 703 | 5 415 | 5 863 | 6 108 | 7 004 | 7 301 | 7 502 | 1 127 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 19 656 | 22 616 | 18 755 | 23 415 | 27 415 | 22 749 | 22 778 | 25 052 | 25 278 | 13 614 |
| Equity | 4 655 | 4 496 | 4 865 | 5 680 | 6 143 | 6 401 | 7 304 | 7 606 | 7 807 | 1 434 |
| Long-term debt | 15 000 | 18 118 | 13 887 | 17 729 | 21 268 | 16 342 | 15 470 | 17 444 | 17 469 | 11 755 |
| Short-term debt | 1 | 2 | 4 | 5 | 5 | 7 | 4 | 2 | 2 | 426 |
| Total debt | 15 001 | 18 120 | 13 891 | 17 734 | 21 273 | 16 349 | 15 474 | 17 446 | 17 471 | 12 181 |
EBITDA margin
-1700000.0%
This company
15.8%
Market median
-10759594% vs market
20152024
Equity ratio
10.5%
This company
38.2%
Market median
-73% vs market
20152024
Return on equity
78.6%
This company
18.4%
Market median
+327% vs market
20152024
Net profit margin
112700000.0%
This company
8.1%
Market median
+1391357925% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
8.49×
This company
0.62×
Market median
-1269% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PM Auditor Substitute | Auditor Substitute | 2020 | — | — |
CJ | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Frontier Pharma AB (this company)
Chemotechnique IncChemotechnique Diagnostics LtdCHEMOTECHNIQUE INCCHEMOTECHNIQUE DIAGNOSTICS LTDBoard members of Frontier Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Patric Mathias Andersson | Auditor Substitute | 0 companies |
| Carl Jesper Sturesson | Audit | 0 companies |
| Lena Marie Niklasson | Board of Directors | 0 companies |
| Jenny Helena Friman | Board of Directors | 0 companies |
| Bo Johan Niklas Niklasson | Chairman | 0 companies |
| David M N Alsheimer-Niklasson | Chairman | 0 companies |
| Eva Catarina Bodin | Deputy Board Member | 0 companies |